Estrogen upregulates NR4A1 to counter TGF beta induced pulmonary fibrosis therapeutic insights for IPF

Key Points

• Pulmonary fibrosis may be countered by the upregulation of NR4A1 due to estrogen exposure, enhancing therapeutic options.
• NR4A1 expression increased with estrogen, reflecting its role in combating the effects of TGF beta in pulmonary fibrosis.
• Assessment involved examining estrogen's impact on NR4A1 levels, specifically within the context of TGF beta signaling.
• Highlights the potential for future therapies targeting estrogen and NR4A1 pathways in treating IPF and related fibrotic diseases.